$\require{mediawiki-texvc}$
  • 검색어에 아래의 연산자를 사용하시면 더 정확한 검색결과를 얻을 수 있습니다.
  • 검색연산자
검색연산자 기능 검색시 예
() 우선순위가 가장 높은 연산자 예1) (나노 (기계 | machine))
공백 두 개의 검색어(식)을 모두 포함하고 있는 문서 검색 예1) (나노 기계)
예2) 나노 장영실
| 두 개의 검색어(식) 중 하나 이상 포함하고 있는 문서 검색 예1) (줄기세포 | 면역)
예2) 줄기세포 | 장영실
! NOT 이후에 있는 검색어가 포함된 문서는 제외 예1) (황금 !백금)
예2) !image
* 검색어의 *란에 0개 이상의 임의의 문자가 포함된 문서 검색 예) semi*
"" 따옴표 내의 구문과 완전히 일치하는 문서만 검색 예) "Transform and Quantization"
쳇봇 이모티콘
안녕하세요!
ScienceON 챗봇입니다.
궁금한 것은 저에게 물어봐주세요.

논문 상세정보

Niclosamide: Beyond an antihelminthic drug

Cellular signalling v.41 , 2018년, pp.89 - 96  
Abstract

Abstract Niclosamide is an oral antihelminthic drug used to treat parasitic infections in millions of people worldwide. However recent studies have indicated that niclosamide may have broad clinical applications for the treatment of diseases other than those caused by parasites. These diseases and symptoms may include cancer, bacterial and viral infection, metabolic diseases such as Type II diabetes, NASH and NAFLD, artery constriction, endometriosis, neuropathic pain, rheumatoid arthritis, sclerodermatous graft-versus-host disease, and systemic sclerosis. Among the underlying mechanisms associated with the drug actions of niclosamide are uncoupling of oxidative phosphorylation, and modulation of Wnt/β-catenin, mTORC1, STAT3, NF-κB and Notch signaling pathways. Here we provide a brief overview of the biological activities of niclosamide, its potential clinical applications, and its challenges for use as a new therapy for systemic diseases. Highlights Niclosamide is an oral antihelminthic drug used to treat parasitic infections. Niclosamide is a multifunctional drug inhibiting multiple signaling pathways and biological processes. Niclosamide has biological activities potentially against systemic diseases.

  

참고문헌 (108)

  1. 1. 1 Andrews P. Thyssen J. Lorke D. The biology and toxicology of molluscicides, Bayluscide Pharmacol. Ther. 19 1983 245 295 
  2. 2. 2 Pearson R.D. Hewlett E.L. Niclosamide therapy for tapeworm infections Ann. Intern. Med. 102 1985 550 551 3977200 
  3. 3. 3 WHO The Selection and Use of Essential Medicines 2007 World Health Organization Geneva 
  4. 4. 4 Weinbach E.C. Garbus J. Mechanism of action of reagents that uncouple oxidative phosphorylation Nature 221 1969 1016 4180173 
  5. 5. 5 Williamson R.L. Metcalf R.L. Salicylanilides: a new group of active uncouplers of oxidative phosphorylation Science 158 1967 1694 1695 (New York, N.Y.) 4228706 
  6. 6. 6 Frayha G.J. Smyth J.D. Gobert J.G. Savel J. The mechanisms of action of antiprotozoal and anthelmintic drugs in man Gen. Pharmacol. 28 1997 273 299 9013207 
  7. 7. 7 Swan G.E. The pharmacology of halogenated salicylanilides and their anthelmintic use in animals J. S. Afr. Vet. Assoc. 70 1999 61 70 10855824 
  8. 8. 8 Kebebew E. Reiff E. Duh Q.Y. Clark O.H. McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J. Surg. 30 2006 872 878 16680602 
  9. 9. 9 Satoh K. Zhang L. Zhang Y. Chelluri R. Boufraqech M. Nilubol N. Patel D. Shen M. Kebebew E. Identification of Niclosamide as a novel anticancer agent for adrenocortical carcinoma Clin. Cancer Res. 22 2016 3458 3466 26873959 
  10. 10. 10 Donepudi M.S. Kondapalli K. Amos S.J. Venkanteshan P. Breast cancer statistics and markers J. Cancer Res. Ther. 10 2014 506 511 25313729 
  11. 11. 11 Lu W. Lin C. Roberts M.J. Waud W.R. Piazza G.A. Li Y. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway PLoS One 6 2011 e29290 
  12. 12. 12 Londono-Joshi A.I. Arend R.C. Aristizabal L. Lu W. Samant R.S. Metge B.J. Hidalgo B. Grizzle W.E. Conner M. Forero-Torres A. Lobuglio A.F. Li Y. Buchsbaum D.J. Effect of niclosamide on basal-like breast cancers Mol. Cancer Ther. 13 2014 800 811 24552774 
  13. 13. 13 Fonseca B.D. Diering G.H. Bidinosti M.A. Dalal K. Alain T. Balgi A.D. Forestieri R. Nodwell M. Rajadurai C.V. Gunaratnam C. Tee A.R. Duong F. Andersen R.J. Orlowski J. Numata M. Sonenberg N. Roberge M. Structure-activity analysis of Niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of Rapamycin Complex 1 (mTORC1) signaling J. Biol. Chem. 287 2012 17530 17545 22474287 
  14. 14. 14 Kim S.Y. Kang J.W. Song X. Kim B.K. Yoo Y.D. Kwon Y.T. Lee Y.J. Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells Cell. Signal. 25 2013 961 969 23333246 
  15. 15. 15 Ren X. Duan L. He Q. Zhang Z. Zhou Y. Wu D. Pan J. Pei D. Ding K. Identification of Niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway ACS Med. Chem. Lett. 1 2010 454 459 24900231 
  16. 16. 16 Wang Y.C. Chao T.K. Chang C.C. Yo Y.T. Yu M.H. Lai H.C. Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells PLoS One 8 2013 e74538 
  17. 17. 17 Karakas D. Cevatemre B. Aztopal N. Ari F. Yilmaz V.T. Ulukaya E. Addition of niclosamide to palladium (II) saccharinate complex of terpyridine results in enhanced cytotoxic activity inducing apoptosis on cancer stem cells of breast cancer Bioorg. Med. Chem. 23 2015 5580 5586 26234907 
  18. 18. 18 Pal S.K. Childs B.H. Pegram M. Triple negative breast cancer: unmet medical needs Breast Cancer Res. Treat. 125 2011 627 636 21161370 
  19. 19. 19 Yin L. Gao Y. Zhang X. Wang J. Ding D. Zhang Y. Zhang J. Chen H. Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling Oncotarget 7 2016 42126 42138 27363012 
  20. 20. 20 Liu J. Chen X. Ward T. Pegram M. Shen K. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer Tumour Biol. 37 2016 9825 9835 26810188 
  21. 21. 21 Holmes D. A disease of growth Nature 521 2015 S2 S3 25970455 
  22. 22. 22 Barker N. Clevers H. Mining the Wnt pathway for cancer therapeutics Nat. Rev. Drug Discov. 5 2006 997 1014 17139285 
  23. 23. 23 Chen M.Y. Wang J.B. Lu J.Y. Bond M.C. Ren X.R. Lyerly H.K. Barak L.S. Chen W. The anti-helminthic Niclosamide inhibits Wnt/Frizzled1 signaling Biochemistry 48 2009 10267 10274 19772353 
  24. 24. 24 Osada T. Chen M.Y. Yang X.Y. Spasojevic I. Vandeusen J.B. Hsu D. Clary B.M. Clay T.M. Chen W. Morse M.A. Lyerly H.K. Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations Cancer Res. 71 2011 4172 4182 21531761 
  25. 25. 25 Sack U. Walther W. Scudiero D. Selby M. Kobelt D. Lemm M. Fichtner I. Schlag Peter M. Shoemaker Robert H. Stein U. Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer J. Natl. Cancer Inst. 103 2011 1018 1036 21685359 
  26. 26. 26 Suliman M.A. Zhang Z. Na H. Ribeiro A.L. Zhang Y. Niang B. Hamid A.S. Zhang H. Xu L. Zuo Y. Niclosamide inhibits colon cancer progression through downregulation of the Notch pathway and upregulation of the tumor suppressor miR-200 family Int. J. Mol. Med. 38 2016 776 784 27460529 
  27. 27. 27 Ostrom Q.T. Gittleman H. Liao P. Rouse C. Chen Y. Dowling J. Wolinsky Y. Kruchko C. Barnholtz-Sloan J. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011 Neuro-Oncology 16 Suppl. 4 2014 iv1 i63 25304271 
  28. 28. 28 Zeng T. Cui D. Gao L. Glioma: an overview of current classifications, characteristics, molecular biology and target therapies Front. Biosci. 20 2015 1104 1115 (Landmark edition) 
  29. 29. 29 Wieland A. Trageser D. Gogolok S. Reinartz R. Hofer H. Keller M. Leinhaas A. Schelle R. Normann S. Klaas L. Waha A. Koch P. Fimmers R. Pietsch T. Yachnis A.T. Pincus D.W. Steindler D.A. Brustle O. Simon M. Glas M. Scheffler B. Anticancer effects of niclosamide in human glioblastoma Clin. Cancer Res. 19 2013 4124 4136 23908450 
  30. 30. 30 Siegel R.L. Miller K.D. Jemal A. Cancer statistics, 2015 CA Cancer J. Clin. 65 2015 5 29 25559415 
  31. 31. 31 Li R. You S. Hu Z. Chen Z.G. Sica G.L. Khuri F.R. Curran W.J. Shin D.M. Deng X. Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer PLoS One 8 2013 e74670 
  32. 32. 32 Bigas A. Robert-Moreno A. Espinosa L. The Notch pathway in the developing hematopoietic system Int. J. Dev. Biol. 54 2010 1175 1188 20711994 
  33. 33. 33 Wang A.M. Ku H.H. Liang Y.C. Chen Y.C. Hwu Y.M. Yeh T.S. The autonomous Notch signal pathway is activated by Baicalin and Baicalein but is suppressed by Niclosamide in K562 cells J. Cell. Biochem. 106 2009 682 692 19160421 
  34. 34. 34 Jin Y. Lu Z. Ding K. Li J. Du X. Chen C. Sun X. Wu Y. Zhou J. Pan J. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species Cancer Res. 70 2010 2516 2527 20215516 
  35. 35. 35 Jin B. Wang C. Li J. Du X. Ding K. Pan J. Anthelmintic niclosamide disrupts the interplay of p65 and FOXM1/beta-catenin and eradicates leukemia stem cells in chronic myelogenous leukemia Clin. Cancer Res. 23 2017 789 803 27492973 
  36. 36. 36 Gridelli C. Maione P. Bareschino M.A. Schettino C. Sacco P.C. Ambrosio R. Barbato V. Falanga M. Rossi A. Erlotinib in the treatment of non-small cell lung cancer: current status and future developments Anticancer Res. 30 2010 1301 1310 20530444 
  37. 37. 37 Li R. Hu Z. Sun S.Y. Chen Z.G. Owonikoko T.K. Sica G.L. Ramalingam S.S. Curran W.J. Khuri F.R. Deng X. Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer Mol. Cancer Ther. 12 2013 2200 2212 23894143 
  38. 38. 38 You S. Li R. Park D. Xie M. Sica G.L. Cao Y. Xiao Z.Q. Deng X. Disruption of STAT3 by niclosamide reverses radioresistance of human lung cancer Mol. Cancer Ther. 13 2014 606 616 24362463 
  39. 39. 39 Lee S.L. Son A.R. Ahn J. Song J.Y. Niclosamide enhances ROS-mediated cell death through c-Jun activation Biomed. Pharmacother. 68 2014 619 624 24750999 
  40. 40. 40 Ottaviani G. Jaffe N. The epidemiology of osteosarcoma Cancer Treat. Res. 152 2009 3 13 20213383 
  41. 41. 41 Liao Z. Nan G. Yan Z. Zeng L. Deng Y. Ye J. Zhang Z. Qiao M. Li R. Denduluri S. Wang J. Wei Q. Geng N. Zhao L. Lu S. Wang X. Zhou G. Luu H.H. Haydon R.C. He T.C. Wang Z. The anthelmintic drug Niclosamide inhibits the proliferative activity of human osteosarcoma cells by targeting multiple signal pathways Curr. Cancer Drug Targets 15 2015 726 738 26118906 
  42. 42. 42 Yo Y.-T. Lin Y.-W. Wang Y.-C. Balch C. Huang R.-L. Chan M.W.Y. Sytwu H.-K. Chen C.-K. Chang C.-C. Nephew K.P. Huang T. Yu M.-H. Lai H.-C. Growth inhibition of ovarian tumor?initiating cells by Niclosamide Mol. Cancer Ther. 11 2012 1703 1712 22576131 
  43. 43. 43 Walters Haygood C.L. Arend R.C. Gangrade A. Chettiar S. Regan N. Hassmann C.J. 2nd Li P.K. Hidalgo B. Straughn J.M. Jr. Buchsbaum D.J. Niclosamide analogs for treatment of ovarian cancer Int. J. Gynecol. Cancer 25 2015 1377 1385 26186072 
  44. 44. 44 Arend R.C. Londono-Joshi A.I. Samant R.S. Li Y. Conner M. Hidalgo B. Alvarez R.D. Landen C.N. Straughn J.M. Buchsbaum D.J. Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer Gynecol. Oncol. 134 2014 112 120 24736023 
  45. 45. 45 King M.L. Lindberg M.E. Stodden G.R. Okuda H. Ebers S.D. Johnson A. Montag A. Lengyel E. MacLean Ii J.A. Hayashi K. WNT7A/β-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer Oncogene 34 2015 3452 3462 25174399 
  46. 46. 46 Chandrasekar T. Yang J.C. Gao A.C. Evans C.P. Mechanisms of resistance in castration-resistant prostate cancer (CRPC) Trans. Androl. Urol. 4 2015 365 380 
  47. 47. 47 Tran C. Ouk S. Clegg N.J. Chen Y. Watson P.A. Arora V. Wongvipat J. Smith-Jones P.M. Yoo D. Kwon A. Wasielewska T. Welsbie D. Chen C.D. Higano C.S. Beer T.M. Hung D.T. Scher H.I. Jung M.E. Sawyers C.L. Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 324 2009 787 790 (New York, N.Y.) 19359544 
  48. 48. 48 Crona D.J. Milowsky M.I. Whang Y.E. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance Clin. Pharmacol. Ther. 98 2015 582 589 26331358 
  49. 49. 49 Liu C. Lou W. Zhu Y. Nadiminty N. Schwartz C.T. Evans C.P. Gao A.C. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer Clin. Cancer Res. 20 2014 3198 3210 24740322 
  50. 50. 50 Liu C. Lou W. Armstrong C. Zhu Y. Evans C.P. Gao A.C. Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via STAT3-AR axis inhibition Prostate 75 2015 1341 1353 25970160 
  51. 51. 51 Hu C.D. Choo R. Huang J. Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure Front. Oncol. 5 2015 90 25927031 
  52. 52. 52 Ippolito J.E. Brandenburg M.W. Ge X. Crowley J.R. Kirmess K.M. Som A. D'Avignon D.A. Arbeit J.M. Achilefu S. Yarasheski K.E. Milbrandt J. Extracellular pH modulates neuroendocrine prostate cancer cell metabolism and susceptibility to the mitochondrial inhibitor Niclosamide PLoS One 11 2016 e0159675 
  53. 53. 53 Murai M. Oya M. Renal cell carcinoma: etiology, incidence and epidemiology Curr. Opin. Urol. 14 2004 229 233 15205579 
  54. 54. 54 Chen S.C. Kuo P.L. Bone Metastasis from Renal Cell Carcinoma Int. J. Mol. Sci. 17 2016 e987 
  55. 55. 55 Zhao J. He Q. Gong Z. Chen S. Cui L. Niclosamide suppresses renal cell carcinoma by inhibiting Wnt/beta-catenin and inducing mitochondrial dysfunctions SpringerPlus 5 2016 1436 27652012 
  56. 56. 56 Fogel N. Tuberculosis: a disease without boundaries Tuberculosis 95 2015 527 531 (Edinburgh, Scotland) 26198113 
  57. 57. 57 Sun Z. Zhang Y. Antituberculosis activity of certain antifungal and antihelmintic drugs Tuber. Lung Dis. 79 1999 319 320 10707260 
  58. 58. 58 de Carvalho L.P.S. Darby C.M. Rhee K.Y. Nathan C. Nitazoxanide disrupts membrane potential and intrabacterial pH homeostasis of Mycobacterium tuberculosis ACS Med. Chem. Lett. 2 2011 849 854 22096616 
  59. 59. 59 Iacobino A. Piccaro G. Giannoni F. Mustazzolu A. Fattorini L. Mycobacterium tuberculosis is selectively killed by Rifampin and Rifapentine in hypoxia at neutral pH Antimicrob. Agents Chemother. 61 61 2017 16 e02296 
  60. 60. 60 Piccaro G. Giannoni F. Filippini P. Mustazzolu A. Fattorini L. Activities of drug combinations against Mycobacterium tuberculosis grown in aerobic and hypoxic acidic conditions Antimicrob. Agents Chemother. 57 2013 1428 1433 23295931 
  61. 61. 61 Friebe S. van der Goot F.G. Burgi J. The Ins and Outs of Anthrax Toxin Toxins 8 3 2016 69 10.3390/toxins8030069 
  62. 62. 62 Zhu P.J. Hobson J.P. Southall N. Qiu C. Thomas C.J. Lu J. Inglese J. Zheng W. Leppla S.H. Bugge T.H. Austin C.P. Liu S. Quantitative high-throughput screening identifies inhibitors of anthrax-induced cell death Bioorg. Med. Chem. 17 2009 5139 5145 19540764 
  63. 63. 63 Cegelski L. Marshall G.R. Eldridge G.R. Hultgren S.J. The biology and future prospects of antivirulence therapies Nat. Rev. Microbiol. 6 2008 17 27 18079741 
  64. 64. 64 Imperi F. Massai F. Ramachandran Pillai C. Longo F. Zennaro E. Rampioni G. Visca P. Leoni L. New life for an old drug: the anthelmintic drug niclosamide inhibits Pseudomonas aeruginosa quorum sensing Antimicrob. Agents Chemother. 57 2013 996 1005 23254430 
  65. 65. 65 Benfield T. Espersen F. Frimodt-Moller N. Jensen A.G. Larsen A.R. Pallesen L.V. Skov R. Westh H. Skinhoj P. Increasing incidence but decreasing in-hospital mortality of adult Staphylococcus aureus bacteraemia between 1981 and 2000 Clin. Microbiol. Infect. 13 2007 257 263 17391379 
  66. 66. 66 Rajamuthiah R. Fuchs B.B. Conery A.L. Kim W. Jayamani E. Kwon B. Ausubel F.M. Mylonakis E. Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus PLoS One 10 2015 e0124595 
  67. 67. 67 Lou Z. Sun Y. Rao Z. Current progress in antiviral strategies Trends Pharmacol. Sci. 35 2014 86 102 24439476 
  68. 68. 68 Wu C.J. Jan J.T. Chen C.M. Hsieh H.P. Hwang D.R. Liu H.W. Liu C.Y. Huang H.W. Chen S.C. Hong C.F. Lin R.K. Chao Y.S. Hsu J.T. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide Antimicrob. Agents Chemother. 48 2004 2693 2696 15215127 
  69. 69. 69 Jurgeit A. Moese S. Roulin P. Dorsch A. Lotzerich M. Lee W.M. Greber U.F. An RNA replication-center assay for high content image-based quantifications of human rhinovirus and coxsackievirus infections Virol. J. 7 2010 264 20937137 
  70. 70. 70 Jurgeit A. McDowell R. Moese S. Meldrum E. Schwendener R. Greber U.F. Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects PLoS Pathog. 8 2012 e1002976 
  71. 71. 71 Staples J.E. Breiman R.F. Powers A.M. Chikungunya fever: an epidemiological review of a re-emerging infectious disease Clin. Infect. Dis. 49 2009 942 948 19663604 
  72. 72. 72 Wang Y.M. Lu J.W. Lin C.C. Chin Y.F. Wu T.Y. Lin L.I. Lai Z.Z. Kuo S.C. Ho Y.J. Antiviral activities of niclosamide and nitazoxanide against chikungunya virus entry and transmission Antivir. Res. 135 2016 81 90 27742486 
  73. 73. 73 Heymann D.L. Hodgson A. Sall A.A. Freedman D.O. Staples J.E. Althabe F. Baruah K. Mahmud G. Kandun N. Vasconcelos P.F. Bino S. Menon K.U. Zika virus and microcephaly: why is this situation a PHEIC? Lancet 387 2016 719 721 (London, England) 26876373 
  74. 74. 74 Xu M. Lee E.M. Wen Z. Cheng Y. Huang W.K. Qian X. Tcw J. Kouznetsova J. Ogden S.C. Hammack C. Jacob F. Nguyen H.N. Itkin M. Hanna C. Shinn P. Allen C. Michael S.G. Simeonov A. Huang W. Christian K.M. Goate A. Brennand K.J. Huang R. Xia M. Ming G.L. Zheng W. Song H. Tang H. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen Nat. Med. 22 2016 1101 1107 27571349 
  75. 75. 75 Kaur J. A comprehensive review on metabolic syndrome Cardiol. Res. Pract. 2014 2014 943162 24711954 
  76. 76. 76 Lonardo A. Ballestri S. Marchesini G. Angulo P. Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome Dig. Liver Dis. 47 2015 181 190 25739820 
  77. 77. 77 Jaacks L.M. Siegel K.R. Gujral U.P. Narayan K.M. Type 2 diabetes: a 21st century epidemic Best Pract. Res. Clin. Endocrinol. Metab. 30 2016 331 343 27432069 
  78. 78. 78 Fairweather I. Boray J.C. Fasciolicides: efficacy, actions, resistance and its management Vet. J. 158 1999 81 112 10489266 
  79. 79. 79 Tao H. Zhang Y. Zeng X. Shulman G.I. Jin S. Niclosamide ethanolamine-induced mild mitochondrial uncoupling improves diabetic symptoms in mice Nat. Med. 20 2014 1263 1269 25282357 
  80. 80. 80 Pham T. Dick T.B. Charlton M.R. Nonalcoholic Fatty Liver Disease and Liver Transplantation Clin. Liver Dis. 20 2016 403 417 27063277 
  81. 81. 81 Mederos Y.S.M. Storch U. Gudermann T. Mechanosensitive Gq/11 protein-coupled receptors mediate myogenic vasoconstriction Microcirculation 23 2016 621 625 27344060 
  82. 82. 82 Li S.L. Yan J. Zhang Y.Q. Zhen C.L. Liu M.Y. Jin J. Gao J.L. Xiao X.L. Shen X. Tai Y. Hu N. Zhang X.Z. Sun Z.J. Dong D.L. Niclosamide ethanolamine inhibits artery constriction Pharmacol. Res. 115 2016 78 86 27872020 
  83. 83. 83 Smarr M.M. Kannan K. Buck Louis G.M. Endocrine disrupting chemicals and endometriosis Fertil. Steril. 106 2016 959 966 27424048 
  84. 84. 84 Prather G.R. MacLean J.A. 2nd Shi M. Boadu D.K. Paquet M. Hayashi K. Niclosamide as a potential nonsteroidal therapy for endometriosis that preserves reproductive function in an experimental mouse model Biol. Reprod. 95 2016 1 11 27387869 
  85. 85. 85 Treede R.D. Jensen T.S. Campbell J.N. Cruccu G. Dostrovsky J.O. Griffin J.W. Hansson P. Hughes R. Nurmikko T. Serra J. Neuropathic pain: redefinition and a grading system for clinical and research purposes Neurology 70 2008 1630 1635 18003941 
  86. 86. 86 Ai N. Wood R.D. Yang E. Welsh W.J. Niclosamide is a negative allosteric modulator of Group I Metabotropic Glutamate Receptors: implications for neuropathic pain Pharm. Res. 33 2016 3044 3056 27631130 
  87. 87. 87 Zhang Y.K. Huang Z.J. Liu S. Liu Y.P. Song A.A. Song X.J. WNT signaling underlies the pathogenesis of neuropathic pain in rodents J. Clin. Invest. 123 2013 2268 2286 23585476 
  88. 88. 88 Nogueira E. Gomes A. Preto A. Cavaco-Paulo A. Update on therapeutic spproaches for Rheumatoid Arthritis Curr. Med. Chem. 23 2016 2190 2203 27149868 
  89. 89. 89 Liang L. Huang M. Xiao Y. Zen S. Lao M. Zou Y. Shi M. Yang X. Xu H. Inhibitory effects of niclosamide on inflammation and migration of fibroblast-like synoviocytes from patients with rheumatoid arthritis Inflamm. Res. 64 2015 225 233 25708600 
  90. 90. 90 Huang M. Zeng S. Qiu Q. Xiao Y. Shi M. Zou Y. Yang X. Xu H. Liang L. Niclosamide induces apoptosis in human rheumatoid arthritis fibroblast-like synoviocytes Int. Immunopharmacol. 31 2016 45 49 26703449 
  91. 91. 91 Im A. Hakim F.T. Pavletic S.Z. Novel targets in the treatment of chronic graft-versus-host disease Leukemia 31 2017 543 554 27899803 
  92. 92. 92 Morin F. Kavian N. Nicco C. Cerles O. Chereau C. Batteux F. Improvement of Sclerodermatous Graft-Versus-Host Disease in mice by Niclosamide J. Invest. Dermatol. 136 2016 2158 2167 27424318 
  93. 93. 93 Pattanaik D. Brown M. Postlethwaite B.C. Postlethwaite A.E. Pathogenesis of Systemic Sclerosis Front. Immunol. 6 2015 272 26106387 
  94. 94. 94 Morin F. Kavian N. Nicco C. Cerles O. Chereau C. Batteux F. Niclosamide prevents Systemic Sclerosis in a reactive oxygen species-induced mouse model J. Immunol. 197 2016 3018 3028 27613696 
  95. 95. 95 Bertrand F.E. Angus C.W. Partis W.J. Sigounas G. Developmental pathways in colon cancer: crosstalk between WNT, BMP, Hedgehog and Notch Cell Cycle 11 2012 4344 4351 23032367 
  96. 96. 96 Collu G.M. Hidalgo-Sastre A. Brennan K. Wnt-Notch signalling crosstalk in development and disease Cell. Mol. Life Sci. 71 2014 3553 3567 24942883 
  97. 97. 97 Fragoso M.A. Patel A.K. Nakamura R.E. Yi H. Surapaneni K. Hackam A.S. The Wnt/β-catenin pathway cross-talks with STAT3 signaling to regulate survival of retinal pigment epithelium cells PLoS One 7 2012 e46892 
  98. 98. 98 Hassanian S.M. Ardeshirylajimi A. Dinarvand P. Rezaie A.R. Inorganic polyphosphate promotes cyclin D1 synthesis through activation of mTOR/Wnt/β-catenin signaling in endothelial cells J. Thromb. Haemost. 14 2016 2261 2273 27546592 
  99. 99. 99 Kay S.K. Harrington H.A. Shepherd S. Brennan K. Dale T. Osborne J.M. Gavaghan D.J. Byrne H.M. The role of the Hes1 crosstalk hub in Notch-Wnt interactions of the intestinal crypt PLoS Comput. Biol. 13 2017 e1005400 
  100. 100. 100 Nakamura T. Tsuchiya K. Watanabe M. Crosstalk between Wnt and Notch signaling in intestinal epithelial cell fate decision J. Gastroenterol. 42 2007 705 710 17876539 
  101. 101. 101 Mook R.A. Jr. Ren X.R. Wang J. Piao H. Barak L.S. Kim Lyerly H. Chen W. Benzimidazole inhibitors from the Niclosamide chemotype inhibit Wnt/β-catenin signaling with selectivity over effects on ATP homeostasis Bioorg. Med. Chem. 25 2017 1804 1816 28233680 
  102. 102. 102 Yang W. de Villiers M.M. Effect of 4-sulphonato-calix[n]arenes and cyclodextrins on the solubilization of niclosamide, a poorly water soluble anthelmintic AAPS J. 7 2005 E241 E248 16146345 
  103. 103. 103 Andrews P. Thyssen J. Lorke D. The biology and toxicology of molluscicides, Bayluscide Pharmac. Ther. 19 1983 245 295 (Very limited pharmacokinetic data in humans exists) 
  104. 104. 104 Merschjohann K. Steverding D. In vitro trypanocidal activity of the anti-helminthic drug niclosamide Exp. Parasitol. 118 2008 637 640 18226810 
  105. 105. 105 Chang Y.-W. Yeh T.-K. Lin K.-T. Chen W.-C. Yao H.-T. Lan S.-J. Wu Y.-S. Hsieh H.-P. Chen C.-M. Chen C.-T. Pharmacokinetics of anti-SARS-CoV agent niclosamide and its analogs in rats Yaowu Shipin Fenxi 14 2006 329 333 
  106. 106. 106 Ye Y. Zhang X. Zhang T. Wang H. Wu B. Design and evaluation of injectable niclosamide nanocrystals prepared by wet media milling technique Drug Dev. Ind. Pharm. 41 2015 1416 1424 25204767 
  107. 107. 107 Lin C.K. Bai M.Y. Hu T.M. Wang Y.C. Chao T.K. Weng S.J. Huang R.L. Su P.H. Lai H.C. Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer Oncotarget 7 2016 8993 9006 26848771 
  108. 108. 108 Mook R.A. Jr. Wang J. Ren X.R. Chen M. Spasojevic I. Barak L.S. Lyerly H.K. Chen W. Structure-activity studies of Wnt/beta-catenin inhibition in the Niclosamide chemotype: identification of derivatives with improved drug exposure Bioorg. Med. Chem. 23 2015 5829 5838 26272032 

DOI 인용 스타일

"" 핵심어 질의응답